Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Female infertility Age: Adult |
Dose: Intramuscular or Subcutaneous injection – 75-150 units of follicle-stimulating hormone Frequency: daily Note: Adjust gradually until adequate response is achieved. Treatment is stopped and followed after 1 or 2 days by single dose of chorionic gonadotrophin 5000-10,000 units. In menstruating patients, start within the first 7 days of menstrual cycle. Stop treatment if no response is seen in 3 weeks. Course may be repeated twice more, if necessary. |
|
Indication: Female infertility Age: Adult |
Dose: Intramuscular or Subcutaneous injection – 3 equal doses, each providing 225-375 units of follicle-stimulating hormone Frequency: alternate days Note: Followed by chorionic gonadotrophin 1 week after the first dose. Stop treatment if no response is seen in 3 weeks. Course may be repeated twice more, if necessary. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Administration
- For injection only
- Must be administered by healthcare professional
Side Effect
- Ovarian hyperstimulation
- risk of multiple pregnancy and miscarriage
- hypersensitivity and local reactions at Injection site
- nausea
- vomiting
- joint pain
- fever
- In men
- gynecomastia
- acne
- weight gain
- Rupture of ovarian cysts and intraperitoneal haemorrhage
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Drugs with luteinising hormone activity
|
May increase risk of ovarian hyperstimulation syndrome
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Ovarian Cysts/Enlargement (not from PCOS)
|
Risk of ovarian complications
|
|
Tumors of Reproductive Organs
|
May stimulate tumor growth
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 2°C to 8°C, Do not freeze. Store below 25°C for single period of not more than 3 months. Protect from light and keep in dry place. The reconstituted solution of the vial should be used immediately after piercing of the rubber stopper. Discard any remaining solution.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.